Price movement over the last 24 hours
ADMA Biologics Inc vs Amplify Transformational Data Sharing ETF — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Amplify Transformational Data Sharing ETF trades at $62.02. The key difference: Amplify Transformational Data Sharing ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | BLOK | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $74.10 |
52-Week Low | $7.60 | $47.36 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BLOK trades at $63.47, up 3.07% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock faces resistance at $64 and support at $62. Recent news highlights the ETF's exposure to AI infrastructure and Bitcoin mining stocks, though analyst sentiment has turned cautious due to increased crypto market correlation.
The outlook remains neutral with technical indicators divided and fundamental data limited. Key risks include reliance on volatile crypto markets and competitive ETF pressures. Analyst consensus suggests holding pending clearer catalysts from AI infrastructure growth or Bitcoin market stabilization.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →